Павлов В. Н., Урманцев М. Ф., Дубровин В. Н. Диагностика опухоль-ассоциированных макрофагов и удаленных лимфатических узлов у больных раком мочевого пузыря после радикальной цистэктомии. Медицинский вестник Башкортостана. 2025;20(2):104-109.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries / Sung H. [et al.] // CA Cancer J Clin. – 2021. – Vol. 71, №3. – P. 209-249. – DOI: 10.3322/caac.21660.
2. Хасанова, Г.М. Токсичные и эссенциальные микроэлементы в организме человека крупного промышленного города / Г.М. Хасанова, З.А. Янгуразова // Экология урбанизированных территорий. – 2007. – №3. – С. 28-30.
3. Schneider, A.K. The multifaceted immune regulation of bladder cancer / Schneider, A.K., Chevalier, M.F., Derré, L. // Nat Rev Urol. – 2019. – Vol. 16, №10. – P. 613-630. – DOI: 10.1038/s41585-019-0226-y.
4. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines / Witjes J.A. [et al.] // Eur Urol. – 2021. – Vol. 79, №1. – P. 82-104. – DOI: 10.1016/j.eururo.2020.03.055.
5. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades / Zehnder P. [et al.] // BJU Int. – 2013. – Vol. 112, №2. – P. E51-8. – DOI: 10.1111/bju.12215.
6. Role of tumor microenvironment in tumorigenesis / Wang, M. [et al.] // J Cancer. – 2017. – Vol. 8, №5. – P. 761-73.
7. Metabolism within the tumor microenvironment and its implication on cancer progression: an ongoing therapeutic target / Ocaña M. C. [et al.] // Med Res Rev. – 2019. – Vol. 39, №1. – P. 70-113. – DOI: 10.1002/med.21511.
8. Hatogai K. The tumor microenvironment of bladder cancer / Hatogai K., Sweis R.F. // Adv Exp Med Biol. – 2020. – Vol. 1296. – P. 275-90.
9. Macrophage polarity in cancer: A review / Najafi M. [et al.] // J Cell Biochem. – 2019. – Vol. 120, №3. – P. 2756-2765.
10. Harnessing tumor-associated macrophages as aids for cancer immunotherapy / Li X. [et al.] // Mol Cancer. – 2019. – Vol. 18, №1. – P. 177.
11. Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion / Cioni B. [et al.] // Nat Commun. – 2020. – Vol. 11, №1. – P. 4498. – DOI: 10.1038/s41467-020-18313-y.
12. Tumor-associated macrophages as major players in the tumor microenvironment / Chanmee T. [et al.] // Cancers (Basel). – 2014. – Vol. 6, №3. – P. 1670-90. – DOI: 10.3390/cancers6031670.
13. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes / Mantovani A. [et al.] // Trends Immunol. – 2002. – Vol. 23, №11. – P. 549-55. – DOI: 10.1016/s1471-4906(02)02302-5.
14. BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer / Martínez V. G. [et al.] // Clin Cancer Res. – 2017. – Vol. 23, № 23. – P. 7388-99. – DOI: 10.1158/1078-0432.CCR-17-1004.
15. COX2/mPGES1/ PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells / Prima V. [et al.] // Proc Natl Acad Sci USA. – 2017. – Vol. 114, № 5. – P. 1117-22. – DOI: 10.1073/pnas.1612920114.
16. Ovatodiolide, isolated from Anisomeles indica, suppresses bladder carcinogenesis through suppression of mTOR/β-catenin/CDK6 and exosomal miR-21 derived from M2 tumor-associated macrophages / Wu A. T. [et al.] // Toxicol Appl Pharmacol. – 2020. – Vol. 401. – P. 115109.
17. Bladder cancer cells induce immunosuppression of T cells by supporting PD-L1 expression in tumour macrophages partially through interleukin 10 / Wang X. [et al.] // Cell Biol Int. – 2017. – Vol. 41, №2. – P. 177-86. – DOI: 10.1002/cbin.10716.
18. Bladder cancer cells re-educate TAMs through lactate shuttling in the microfluidic cancer microenvironment / Zhao Y. [et al.] // Oncotarget. – 2015. – Vol. 6, №36. – P. 39196-210. – DOI: 10.18632/oncotarget.5538.
19. Tumor-associated macrophages in bladder cancer: biological role, impact on therapeutic response and perspectives for immunotherapy / Leblond, M. M. [et al.] // Cancers (Basel). – 2021. – Vol. 13, №18. – P. 4712. – DOI: 10.3390/cancers13184712.
20. Tumor infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer / Xue Y. [et al.] // Oncol Rep. – 2019. – Vol. 42, №2. – P. 581-594. – DOI: 10.3892/or.2019.7196.
21. Landmarks in the treatment of muscle-invasive bladder cancer / Lobo N. [et al.] // Nat Rev Urol. – 2017. – Vol. 14, №9. – P. 565-574.
22. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses / Zeng, H. [et al.] // Int J Cancer. – 2020. – Vol. 146, №2. – P. 542-552. – DOI: 10.1002/ijc.32715.
23. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer / Sun M. [et al.] // Cancer Immunol Immunother. – 2022. – Vol. 71, №6. – P. 1497-1506. – DOI: 10.1007/s00262-021-03098-w.
24. Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy / Taubert H. [et al.] // Cells. – 2021. – Vol. 10, №1. – P. 159. – DOI: 10.3390/cells10010159.
